
Plenary Lecture 1
Page 01 Symposium 2
Mechanism, Markers and Management Page 20
of Hypercoagulable States Blood Vessel Wall Interaction
P Mannucci, A Tripodi (Italy) Platelet-Polymorphonuclear
Leukocyte
Functional Interactions: Role of
Symposium 1 Adhesive Molecules
Page 09 C Cerletti, V Evangelista, G de
Inhibitors of Blood Coagulation Gaetano (Italy)
Page 28
Molecular Basis for Protein C Consequences of Transcellular
Hereditary Deficiency Biosynthesis of Leukotriene C4 on
M Aiach, S Gandrille (France) Organ Function J Maclouf, A Sala, G Rossoni, F Berti, R Muller-
Peddinghaus, G Folco (France)

Tuesday 15 October
Symposium 3
Injury Models of Vascular Endothelium
Page 37
Injury Models of Vascular
Endothelium: Apoptosis and Loss
of Thromboresistance induced by a
Viral Protein
A Eldor, D Sela-Donenfeld,
M Korner M Pick, N Resnick-Roguel,
A Panet (Israel)
Page 46
Dietary Fatty Acids in athero-
thrombogenesis Influence of Palm
Oil Ingestion
N de Bosch, V Bosch, R Apitz
(Venezuela)
Which Experimental Model to Choose to Study Arterial Thrombosis and Evaluate Potentially useful Therapeutics

P Andre, C Balledi, Solleri, M Bonneau, G Pignaud, P Hainaud, K Azzam, L Drouet (France)

New Antiplatelet Agents

Modulating Platelet Function with Selective Thrombin Inhibitors

M Verstraete (Belgium)

New thoughts on Strategies for Modulating Platelet Function through the Inhibition of Surface Receptors

A Nurden, (France)

Tissue Factor Pathway Inhibitor: Regulation of its Inhibitory Activity by Phospholipid Surfaces

T Lindhout, I Salemink, J Franssen, S Valentin, GM Willems (Netherlands)

Analysis of the Kinetics of Factor X Activation by Tissue Factor-Factor Viila

Y Nemerson (USA)

Platelet Activation: New Aspects

JEB Fox (USA)

Genetic Analysis of the Plasminogen and Coagulation in Mice

P Carmeliet, D Collen (Belgium)

New Agents and Treatments of Venous Tissue Factor Pathway Inhibitor Thrombosis (TFPI): An Update

P Sandset (Norway)

Comparison of the Relative Efficacy and Safety of Low Molecular Weight Heparins and unfractionated Heparin Dynamic and Rheological Aspects for the treatment of Venous Thrombosis

J Hirsh (Canada)
Hemorheological Profile in Patients with Cardiovascular Risk Factors Symposium 8
A Vayà-Montana, M Martinez, Signal Transduction During Platelet Activation
J Daimau, M Labios, J Aznar (Spain) Activation
Page 171 Page 199
Effect of HMG-CoA reductase Platelet Activation Via Trimeric GTP-inhibitors on the Red Blood Cell Binding Proteins
Membrane Lipids and JWN Akkerman, G van Willigen
Hemorheological Parameters in (The Netherlands) Patients Affected by Familial Hypercholesterolemia
M Martinez, A Vaya, R Marti, L Gil, I Lluch, R Carmena, J Aznar (Spain)
Page 177
Influence of Hypoxia and Hypoxia-reoxygenation on P-selectin Expression
C Closse, M Seigneur, M Renard, A Pruvost, MR Boisseau (France)
Page 182
Effect of Buflomedil on the Neutrophil-Endothelial cell Interaction under Inflammatory and Hypoxia conditions
M R Boisseau, A Pruvost, M Renard, C Closse, F Belloc, M Seigneur, M Maurel (France)

Thursday 17 October

Plenary Lecture 7 Symposium 11
Page 244
Leukocyte Extravasion
E Dejana, A Zanetti, A del Maschio Symposium 12 (Italy) An Up-date on Monitoring Anticoagulant Therapy
Symposium 9
Critical Evaluation of Clinical Trials Page 248
Precision and Accuracy of the Page 220 International normalized ratio
Management of Venous in Oral Anticoagulant control Thromboembolism: Optimization A van den Besselaar by Clinical Trials (The Netherlands)
A Turpie (Canada) Page 266
Symposium 10 The European Concerted Action on Thrombomodulin and TFPI Anticoagulation
L Poilier, TW Barrocliffe, AHMP
Page 227 van den Besselaar, J Jespersen,
Directed Search for A Tripodi, D Noughton (UK)
Thrombomodulin Gene Mutations Plenary Lecture 8
H Ireland, K Kyriakoulis,
DA Lane, (UK) Page 269
Plaque Rupture, Thrombosis and Page 233 Therapeutic Implications
Considering Cellular V Fuster, J Badimon, J Chesebro,
Thrombomodulin Distribution and J Fallon (USA)
its Modulating Factors can Facilitate the Use of Plasma Plenary Lecture 9
Thrombomodulin as a Reliable Endothelial Marker Page 285
MC Boffa (France The Anti GP- IIb-IIIa Agents: Fundamental and Clinical Aspects B Collet, K Anderson, H Weisman (USA)
VI Friday 18 October

Plenary Lecture 10 Symposium 15
Page 293 Antiphospholipid Antibodies Fibrin-Selective Thrombolytic Therapy with Recombinant Page 339
Staphylokinase Pathogenic Role of Antiprotein-D Collen, S Vanderschueren, Phospholipid Antibodies F van de Werf (Belgium) LO Carreras, RR Forastierio (Argentina)
Symposium 13 Page 357 APC Resistance Antiphospholipid-Protein Page 300 Antibodies: Clinical Use of Inherited Resistance to Activated Laboratory Test Results protein C caused by Presence of DA Triplett (USA) the FV:Q506 Allele as a Basis of Venous Thrombosis Symposium 16
B Dahlbäck, B Zöller, A Hillarp New Agents for Prophylaxis of Venous (Sweden) Thromboembolism Page 314 Page 367
Diagnosis and Clinical New Antithrombotic Agents for the Characteristics of Inherited Prevention and Treatment of Deep Activated Protein C (APC) Vein Thrombosis Resistance B Boneu (France)
MM Samama, D Simon,
MH Horelou, M Trossaert, Page 378
I Elalamy, J Conard (France) Prolonged prophylaxis against venous Thromboembolism

D Bergqvist (Sweden)

Symposium 14

Page 330

Regulation of Fibrinogen Biosynthesis by Cytokines: Consequences on the Vascular Risk

M Vasse, J Paysant, J Soria,

JP Collet, JP Vannier, C Soria

(France)

VII